Advertisement News Archives - Page 2167 of 5237 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 23, 2026

BoomRay and Novartis Pharma sign $900m deal for radioligand therapy

China-based clinical-stage biotechnology company BoomRay Pharmaceuticals and Novartis Pharma have signed an exclusive worldwide licence deal for an undisclosed preclinical radioligand therapy (RLT) asset in a deal worth up to $900m.

BoomRay and Novartis Pharma sign $900m deal for radioligand therapy